ABSTRACT
OBJECTIVE: Previous studies showed alterations of brain function in the ventromedial prefrontal cortex of schizophrenia patients. Also, neurochemical changes, especially GABA level alteration, have been found in the medial prefrontal cortex of schizophrenia patients. However, the relationship between GABA level in the ventromedial prefrontal cortex and brain functional activity in schizophrenia patients remains unexplored. METHODS: In total, 23 drug-naïve, first-episode psychosis patients and 26 matched healthy controls completed the study. The single voxel proton magnetic resonance spectroscopy data were acquired in ventromedial prefrontal cortex region, which was used as the seed region for resting-state functional connectivity analysis. The proton magnetic resonance spectroscopy data were processed to quantify the concentrations of GABA+, glutamine and glutamate, and N-acetylaspartate in ventromedial prefrontal cortex. Spearman correlation analysis was used to examine the relationship between metabolite concentration, functional connectivity and clinical variables. Pearson correlation analysis was used to examine the relationship between GABA+ concentration and functional connectivity value. RESULTS: In first-episode psychosis patients, GABA+ level in ventromedial prefrontal cortex was higher and was positively correlated with ventromedial prefrontal cortex-left middle orbital frontal cortex functional connectivity. N-acetylaspartate level was positively correlated with positive symptoms, and the functional connectivity between ventromedial prefrontal cortex and left precuneus was negatively associated with negative symptoms of first-episode psychosis patients. CONCLUSION: Our results indicated that ventromedial prefrontal cortex functional connectivity changes were positively correlated with higher local GABA+ level in first-episode psychosis patients. The altered neurochemical concentration and functional connectivity provide insights into the pathology of schizophrenia.
Subject(s)
Prefrontal Cortex , Psychotic Disorders , Brain/diagnostic imaging , Humans , Magnetic Resonance Imaging , Prefrontal Cortex/diagnostic imaging , Proton Magnetic Resonance Spectroscopy , Psychotic Disorders/diagnostic imagingABSTRACT
OBJECTIVE: The argument surrounding the safety and effectiveness of interventions for the population of individuals at a clinical high risk of developing psychosis has been ongoing for the past 30 years. However, few studies have assessed the needs of this special young population, who are struggling with the recent onset of psychotic symptoms. METHOD: The sample consisted of 171 family members of 108 clinical high-risk individuals included from the ShangHai at Risk for Psychosis research programme. A 'WeChat' group was established to provide mutual support. There were 22,007 valid messages sent within the group between 1 April 2015 and 27 June 2016. Chat records were subsequently analysed to determine the needs of families during intervention at the early stages of psychosis. RESULTS: Families of clinical high-risk individuals were highly involved in the entire medical process, and the major concerns of the families of clinical high-risk individuals focused on both functional recovery and medication. The themes of 'take medication', 'go to school' and 'study in school' were often discussed within the group. CONCLUSION: A family-focused intervention targeting functional recovery and real-time professional explanations of medication would meet the major needs of families of Chinese clinical high-risk individuals.
Subject(s)
Family , Health Services Needs and Demand , Online Social Networking , Psychosocial Support Systems , Psychotic Disorders/therapy , Self-Help Groups , Adolescent , Adult , China , Female , Humans , Male , Psychotic Disorders/drug therapy , Psychotic Disorders/rehabilitation , Risk , Young AdultABSTRACT
OBJECTIVE: This study aimed to examine the overlaps between the Diagnostic and Statistical Manual-5 (DSM-5) Personality Disorders (PDs) in a high-risk clinical population and to explore a transitional model for implementing DSM-5 PDs. METHOD: A sample population of 982 outpatients with at least one diagnosed PD was selected from 3,075 outpatients of the Shanghai Mental Health Center. The diagnostic process comprised of a personality diagnostic questionnaire and a structured clinical interview. RESULTS: 685 (22.3%) patients were diagnosed with at least one of six PDs (antisocial, avoidant, borderline, narcissistic, obsessive-compulsive, and schizotypal) under the alternative DSM-5 model for personality disorders proposed in Section III of the DSM-5. Nearly 20.3% of the subjects with PD met criteria for at least two PDs (of the 685 PD patients/6 PD model). Cluster and principal component analyses suggest a transitional model for the 7 specific PD categories (among the 722 PD patients, the overlapping rate was 24.1%) will be more appropriate for PD diagnosis in China. CONCLUSIONS: Using the simplified PD categories in the alternative DSM-5 model for personality disorders will reduce the overlaps in PD diagnoses in Chinese psychiatric practice, and should be preferred over the DSM-5 PD diagnostic system.
Subject(s)
Diagnostic and Statistical Manual of Mental Disorders , Personality Disorders/diagnosis , Personality , Adult , Antisocial Personality Disorder/diagnosis , China , Female , Humans , Male , Middle Aged , Outpatients/psychology , Surveys and QuestionnairesABSTRACT
OBJECTIVE: Schizophrenia is associated with impairment in prospective memory, the ability to remember to carry out an intended action in the future. It has been established that cue identification (detection of the cue event signaling that an intended action should be performed) and intention retrieval (retrieval of an intention from long-term memory following the recognition of a prospective cue) are two important processes underlying prospective memory. The purpose of this study was to examine prospective memory deficit and underlying cognitive processes in patients with first-episode schizophrenia. METHODS: This study examined cue identification and intention retrieval components of event-based prospective memory using a dual-task paradigm in 30 patients with first-episode schizophrenia and 30 healthy controls. All participants were also administered a set of tests assessing working memory and retrospective memory. RESULTS: Both cue identification and intention retrieval were impaired in patients with first-episode schizophrenia compared with healthy controls ( ps < 0.05), with a large effect size for cue identification (Cohen's d = 0.98) and a medium effect size for intention retrieval (Cohen's d = 0.62). After controlling for working memory and retrospective memory, the difference in cue identification between patients and healthy controls remained significant. However, the difference in intention retrieval between the two groups was no longer significant. In addition, there was a significant inverse relationship between cue identification and negative symptoms ( r = -0.446, p = 0.013) in the patient group. CONCLUSION: These findings suggest that both cue identification and intention retrieval in event-based prospective memory are impaired in patients with first-episode schizophrenia. Cue identification and intention retrieval could be potentially used as biomarkers for early detection and treatment prognosis of schizophrenia. In addition, addressing cue identification deficit through cognitive enhancement training may potentially improve negative symptoms as well.
Subject(s)
Cues , Intention , Memory Disorders/physiopathology , Memory, Episodic , Mental Recall/physiology , Schizophrenia/physiopathology , Adult , Female , Humans , Male , Memory Disorders/etiology , Schizophrenia/complications , Young AdultABSTRACT
There is a growing body of evidence suggesting that patients with psychosis show impaired theory of mind (ToM). However, much remains to be understood as to whether ToM deficits occur in the premorbid or post-onset period of psychosis. Our primary aim was to examine empirically impairment on ToM tasks in a group of individuals with clinical high risk (CHR) of psychosis. Fifty CHR participants identified through the Structured Interview for Prodromal Syndromes and 52 age-/education-matched controls were assessed with a complete standard neuropsychological battery (the MCCB, MATRICS Consensus Cognitive Battery) and a social cognition assessment (Faux Pas Test, FPT). We then examined the association of baseline FPT performance with conversion to psychosis at 12-month follow-up. Compared with controls, the CHR group showed significantly poorer performances on the FPT and most MCCB domains. Significant positive correlations were found between faux pas detection and the MCCB domains of Attention/Vigilance and Working Memory in CHR participants when controlling for age and years of education. Mean scores on the FPT in 14 converters who were diagnosed with full-blown psychosis within 12 months were significantly lower than they were for non-converters. Impairments in ToM ability are acquired earlier in the prodromal stage of psychosis, along with general cognition (such as memory function) deficits. Declines in ToM ability may overlap with the progress of psychosis (the gradual loss insight), sharing similar neural substrates, and reflected by impairments in basic cognitive function.
Subject(s)
Cognition Disorders/etiology , Help-Seeking Behavior , Psychotic Disorders , Recognition, Psychology/physiology , Theory of Mind , Adolescent , Adult , Cognition Disorders/diagnosis , Female , Humans , Male , Neuropsychological Tests , Psychiatric Status Rating Scales , Psychotic Disorders/complications , Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Risk Factors , Statistics, Nonparametric , Surveys and Questionnaires , Young AdultABSTRACT
BACKGROUND: The reported rates of personality disorder (PD) in subjects with schizophrenia (SZ) are quite varied across different countries, and less is known about the heterogeneity of PD among subjects with SZ. We examined the co-morbidity of PD among patients who are in the stable phase of SZ. METHOD: 850 subjects were randomly sampled from patients diagnosed with SZ in psychiatric and psycho-counseling clinics at Shanghai Mental Health Center. Co-morbidity of PDs was assessed through preliminary screening and patients were administered several modules of the SCID-II. Evidence of heterogeneity was evaluated by comparing patients diagnosed with SZ with those who presented with either affective disorder or neurosis (ADN). RESULTS: 204 outpatients (24.0 %) in the stable phase of SZ met criteria for at least one type of DSM-IV PD. There was a higher prevalence of Cluster-A (odd and eccentric PD) and C (anxious and panic PD) PDs in SZ (around 12.0 %). The most prevalent PD was the paranoid subtype (7.65 %). Subjects with SZ were significantly more likely to have schizotypal PD (4.4 % vs. 2.1 %, p = 0.003) and paranoid PD (7.6 % vs. 5.4 %, p = 0.034), but much less likely to have borderline, obsessive-compulsive, depressive, narcissistic and histrionic PD. CONCLUSIONS: These findings suggest that DSM-IV PD is common in patients with SZ than in the general population. Patterns of co-morbidity with PDs in SZ are different from ADN.
Subject(s)
Outpatients/psychology , Personality Disorders/epidemiology , Schizophrenia/epidemiology , Adult , China/epidemiology , Comorbidity , Diagnostic and Statistical Manual of Mental Disorders , Female , Health Surveys , Humans , Male , Middle Aged , Personality Disorders/psychology , Prevalence , Schizophrenic PsychologyABSTRACT
PURPOSE: Well-established segmentation models will suffer performance degradation when deployed on data with heterogeneous features, especially in the field of medical image analysis. Although researchers have proposed many approaches to address this problem in recent years, most of them are feature-adaptation-based adversarial networks, the problems such as training instability often arise in adversarial training. To ameliorate this challenge and improve the robustness of processing data with different distributions, we propose a novel unsupervised domain adaptation framework for cross-domain medical image segmentation. METHODS: In our proposed approach, Fourier transform guided images translation and multi-model ensemble self-training are integrated into a unified framework. First, after Fourier transform, the amplitude spectrum of source image is replaced with that of target image, and reconstructed by the inverse Fourier transform. Second, we augment target dataset with the synthetic cross-domain images, performing supervised learning using the original source set labels while implementing regularization by entropy minimization on predictions of unlabeled target data. We employ several segmentation networks with different hyperparameters simultaneously, pseudo-labels are generated by averaging their outputs and comparing to confidence threshold, and gradually optimize the quality of pseudo-labels through multiple rounds self-training. RESULTS: We employed our framework to two liver CT datasets for bidirectional adaptation experiments. In both experiments, compared to the segmentation network without domain alignment, dice similarity coefficient (DSC) increased by nearly 34% and average symmetric surface distance (ASSD) decreased by about 10. The DSC values were also improved by 10.8% and 6.7%, respectively, compared to the existing model. CONCLUSION: We propose a Fourier transform-based UDA framework, the experimental results and comparisons demonstrate that the proposed method can effectively diminish the performance degradation caused by domain shift and performs best on the cross-domain segmentation tasks. Our proposed multi-model ensemble training strategy can also improve the robustness of the segmentation system.
Subject(s)
Image Processing, Computer-Assisted , Tomography, X-Ray Computed , Humans , Fourier Analysis , EntropyABSTRACT
PURPOSE: Existing medical image segmentation models tend to achieve satisfactory performance when the training and test data are drawn from the same distribution, while they often produce significant performance degradation when used for the evaluation of cross-modality data. To facilitate the deployment of deep learning models in real-world medical scenarios and to mitigate the performance degradation caused by domain shift, we propose an unsupervised cross-modality segmentation framework based on representation disentanglement and image-to-image translation. METHODS: Our approach is based on a multimodal image translation framework, which assumes that the latent space of images can be decomposed into a content space and a style space. First, image representations are decomposed into the content and style codes by the encoders and recombined to generate cross-modality images. Second, we propose content and style reconstruction losses to preserve consistent semantic information from original images and construct content discriminators to match the content distributions between source and target domains. Synthetic images with target domain style and source domain anatomical structures are then utilized for training of the segmentation model. RESULTS: We applied our framework to the bidirectional adaptation experiments on MRI and CT images of abdominal organs. Compared to the case without adaptation, the Dice similarity coefficient (DSC) increased by almost 30 and 25% and average symmetric surface distance (ASSD) dropped by 13.3 and 12.2, respectively. CONCLUSION: The proposed unsupervised domain adaptation framework can effectively improve the performance of cross-modality segmentation, and minimize the negative impact of domain shift. Furthermore, the translated image retains semantic information and anatomical structure. Our method significantly outperforms several competing methods.
Subject(s)
Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Humans , SemanticsABSTRACT
To compare the efficacy and safety of augmenting paroxetine with risperidone, buspirone, valproate, trazodone, or thyroid hormone in patients with treatment-resistant depression (TRD), 225 patients with retrospectively and/or prospectively identified stage II TRD were randomly assigned to receive an 8-week treatment of paroxetine 20 mg/d augmented with risperidone 2 mg/d (n = 45), sodium valproate 600 mg/d (n = 39), buspirone 30 mg/d (n = 46), trazodone 100 mg/d (n = 47), or thyroid hormone 80 mg/d (n = 48). The primary outcome was the remission rate defined as the 17-item Hamilton Rating Scale for Depression score of 7 or less at the end of study. Secondary outcomes included remission rate based on the Self-rating Depression Scale score of 50 or less at the end of study, response rate based on 17-item Hamilton Rating Scale for Depression total score of 50% improvement or greater from baseline, and the change in scores of Clinical Global Impression-Improvement scale, the Short Form 36 Health Survey, and the Life Satisfaction Rating Scale. The remission rates were 26.7% for risperidone, 48.7% for valproate, 32.6% for buspirone, 42.6% for trazodone, and 37.5% for thyroid hormone. There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events. Risperidone, valproate, buspirone, trazodone, or thyroid hormone augmentation to paroxetine 20 mg/d was effective and well tolerated in Chinese patients with TRD. Large-sample studies are warranted to support or refute these findings.
Subject(s)
Depressive Disorder, Major/drug therapy , Paroxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Buspirone/administration & dosage , Buspirone/adverse effects , Buspirone/therapeutic use , China , Double-Blind Method , Drug Resistance , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Paroxetine/administration & dosage , Paroxetine/adverse effects , Pilot Projects , Psychiatric Status Rating Scales , Remission Induction/methods , Risperidone/administration & dosage , Risperidone/adverse effects , Risperidone/therapeutic use , Selective Serotonin Reuptake Inhibitors/administration & dosage , Selective Serotonin Reuptake Inhibitors/adverse effects , Thyroid Hormones/administration & dosage , Thyroid Hormones/adverse effects , Thyroid Hormones/therapeutic use , Trazodone/administration & dosage , Trazodone/adverse effects , Trazodone/therapeutic use , Valproic Acid/administration & dosage , Valproic Acid/adverse effects , Valproic Acid/therapeutic useABSTRACT
Prolactin increase is a common side effect in antipsychotic treatment of schizophrenia, which crucially impacts drug choice and treatment compliance. As previous reviews by our group on this topic have included only few Chinese studies, we aimed to compare and rank antipsychotics based on broader evidence. This systematic review pooled data of 92 included studies from previous systematic review by Huhn et al. and 38 newly-added studies from Chinese-database search, including Chinese databases of China National Knowledge Infrastructure (CNKI), WANFANG DATA, WEIPU Journal Net (VIP) and Sino Biomedicine Service System (SinoMed) up to 20 May 2020. We conducted both network meta-analysis (NMA) and pairwise meta-analysis. The primary outcome was prolactin increase (continuous data). We calculated mean differences (MDs) for prolactin level with 95% confidence intervals (CIs) using random-effects model as primary analysis. 130 RCTs with 25,610 participants were included. Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. The SMD results were not identical to the MD results because consistency and heterogeneity assumption was tested to be different in calculations. Sensitivity analyses removing two studies with massive baseline imbalance or removing Chinese studies with high risk of bias did not affect the result. In contrast to a previous review clozapine and zotepine were no longer associated with decreased prolactin levels compared to placebo. Risperidone's ranking has more implications supported by CINeMA. This NMA draws the conclusion with larger sample size and extends evidence to more literature in this field.
Subject(s)
Antipsychotic Agents , Schizophrenia , Antipsychotic Agents/adverse effects , Humans , Network Meta-Analysis , Prolactin , Risperidone/therapeutic use , Schizophrenia/chemically induced , Schizophrenia/drug therapyABSTRACT
Objectives: Major depressive disorder (MDD) is a serious mental disorder, and there is a great difficulty to diagnose and treat. Hitherto, relatively few studies have explored the correlation between the levels of plasma cell adhesion molecules and MDD. Methods: Thirty outpatients with acute episodes of MDD in Shanghai Mental Health Center and 34 healthy volunteers from the community were recruited as subjects. Protein microarray technology was applied to compared the differences in plasma levels of 17 kinds of adhesion molecular proteins between the two groups. Meanwhile, the diagnostic value of different proteins in depression was discussed by using the receiver operating characteristic curve. Results: The levels of Carcinoembryonic Antigen Related Cell Adhesion Molecule-1(CEACAM-1) and Neural Cell Adhesion Molecule (NrCAM) in MDD patients were significantly higher than those in healthy controls (P < 0.05). The area under ROC curve of CEACAM-1 combined with NrCAM was 0.723, with the sensitivity 0.800 and the specificity 0.676. Conclusion: The plasma levels of CEACAM-1 and NrCAM were significantly up-regulated in MDD, and their combined application was of potential diagnostic value, deserving to expand the sample size for further verification.
ABSTRACT
Compelling recent evidence suggests that microRNAs (miRNAs) regulate specific mRNA transcripts at the transcriptomic level and coordinately influence complex regulatory networks, which may play a crucial role in the pathogenesis of major depressive disorder (MDD) and the treatment effects of antidepressants. To evaluate the possible involvement of miRNAs in the pathophysiology and therapeutic response of MDD, we conducted a miRNA expression array analysis of the peripheral blood mononuclear cells (PBMCs) of 5 depressed patients and 5 healthy controls (HCs). Subsequently, we chose 2 miRNAs for validation with real-time PCR (RT-PCR) analysis pre- and post-treatment in another group of 25 MDD patients and 25 HCs. In the array, 5 miRNAs were differentially expressed in medication-naïve MDD patients compared to HCs, of which 2 miRNAs were upregulated and 3 were downregulated. Furthermore, in comparison with HCs, MDD patients showed significantly lower expression levels of miR-374b and miR-10a before treatment. After 8 weeks of antidepressant treatment, both miR-374b and the miR-10a expression levels in MDD patients were significantly elevated only in responders. In conclusion, these results indicate the involvement of miR-374b and miR-10a in the biological mechanisms and therapeutic response of MDD, and provide new insights for exploring miRNAs as potential biomarkers for MDD.
Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/genetics , MicroRNAs/metabolism , Adult , Antidepressive Agents/pharmacology , Biomarkers/blood , Depressive Disorder, Major/blood , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/drug therapy , Down-Regulation , Drug Monitoring/methods , Female , Humans , Male , MicroRNAs/blood , Middle Aged , Treatment Outcome , Up-Regulation/drug effectsABSTRACT
Accumulated studies have investigated pharmacological interventions for first-episode schizophrenia (FES) patients. However, studies on subsequent treatment steps, which are essential to guide clinicians, are largely missing. This Sequential Multiple-Assignment Randomized Trials comparing Antipsychotic Treatments (SMART-CAT) program intends to evaluate the effectiveness of commonly used antipsychotic drugs in FES patients. The major goals of this study are to examine: 1) what would be the optimal subsequent sequential treatment if the first antipsychotic drug failed; 2) whether clozapine could be used in those first-trial failed and have superior efficacy compared to other atypical antipsychotics. In this article we will report the detail protocol of SMART-CAT. The SMART-CAT is a randomized controlled clinical multicenter trial in which 9 institutions in China will participate. A total of 720 FES patients will be enrolled and followed up for 12 months in this study. The trial includes three treatment phases (each phase lasting for 8 weeks) and a naturalistic follow-up phase; participants who do well on an assigned treatment will remain on that treatment for the duration of the 12-month treatment period, while non-responders will move to the next phase of the study to receive a new treatment. Phase 1 is a randomized controlled trial; patients will be randomly assigned to one of the treatments with oral olanzapine, risperidone, amisulpride, aripiprazole or perphenazine. Subjects who fail to respond after 8 weeks will enter the phase 2 randomization. Phase 2 is an equipoise-stratified randomization trial, and patients will be randomly assigned to oral olanzapine, amisulpride or clozapine for 8 weeks. Subjects who fail to respond after phase 2 will enter an open label trial (phase 3); patients who receive clozapine in phase 2 and fail to respond will be assigned to an extended clozapine treatment or modified electroconvulsive therapy add-on therapy (Phase 3A). Patients who were not assigned to clozapine in phase 2 will be assigned to treatment with clozapine or another SGAs not previously used in phase 1 and 2 (Phase 3B). The primary outcome for the treatment phase is the treatment efficacy rate, which is defined as at least 40% reduction in Positive and Negative Syndrome Scale (PANSS) total score. We hypothesize that clozapine is more therapeutically effective than any other SGAs to patients who failed to meet efficacy criteria in Phase 1, and earlier treatment with clozapine can improve the functional outcomes of schizophrenia patients. As for the naturalistic follow-up phase, time to all-cause treatment failure, marked by its discontinuation is selected as the primary outcome, since it reflects both efficacy and side effects. The all-cause discontinuation is defined as discontinuing for any reasons, including poor efficacy, intolerance of adverse reactions, poor compliance and other reasons. The results of the SMART-CAT trial will provide evidence for the selection of antipsychotics in FES patients who fail to respond to the first trial of an antipsychotic drug. It will also provide evidence for the efficacy and safety of using clozapine in the early phase of schizophrenia treatment by comparing with other SGAs. The study is based on the combination of sequential therapy and dynamic therapy, which can be more suitable to assess the effectiveness of treatment options in the real-world clinical setting. As a result, we hope that this study can provide guidance for an optimal treatment algorithm in first-episode schizophrenia patients. Trial registration: ID NCT03510325 in ClinicalTrials.gov.
Subject(s)
Antipsychotic Agents , Clozapine , Schizophrenia , Antipsychotic Agents/therapeutic use , Benzodiazepines/therapeutic use , China , Clozapine/therapeutic use , Humans , Randomized Controlled Trials as Topic , Schizophrenia/drug therapyABSTRACT
To compare the efficacy and tolerability of antidepressants switch with extended-release venlafaxine (venlafaxine-XR), mirtazapine, and paroxetine in Chinese patients with major depressive disorder who had 2 consecutive unsuccessful antidepressant trials. One hundred fifty adult patients with treatment-resistant depression according to their medical records and/or response to current treatments were randomly assigned to receive fixed-dosage treatment of venlafaxine-XR 225 mg/d (n = 50), mirtazapine 45 mg/d (n = 55), or paroxetine 20 mg/d (n = 45) for 8 weeks. The primary outcome was the remission rates that were defined as a score 7 or lower on the 17-item Hamilton Rating Scale for Depression (HRSD-17). Secondary outcomes included the remission rate defined by the Self-Rating Depression Scale of 50 or lower and the response rate defined by a 50% reduction or greater on the HRSD-17 total score, and the improvement of patients' general health functions. The completion rates were 82% for venlafaxine-XR, 81.8% for mirtazapine, and 82.2% for paroxetine. Only one patient in paroxetine arm discontinued the study owing to an adverse event. The remission rates based on the HRSD-17 were 42.0% for venlafaxine-XR, 36.4% for mirtazapine, and 46.7% for paroxetine. There were no statistical significances between treatment arms in remission rates. Similarly, there were also no significant differences between groups in secondary outcome measure. Venlafaxine-XR, mirtazapine, and paroxetine were equally effective in the treatment of Chinese patients with major depressive disorder who failed at least 2 previous antidepressant treatments. Selecting any of these 3 antidepressants as a third-step antidepressant is a reasonable choice for this group of patients.
Subject(s)
Cyclohexanols/therapeutic use , Depressive Disorder, Major/drug therapy , Mianserin/analogs & derivatives , Paroxetine/therapeutic use , Adult , Antidepressive Agents, Second-Generation/adverse effects , Antidepressive Agents, Second-Generation/therapeutic use , Antidepressive Agents, Tricyclic/adverse effects , Antidepressive Agents, Tricyclic/therapeutic use , China , Cyclohexanols/adverse effects , Delayed-Action Preparations , Double-Blind Method , Drug Resistance , Female , Humans , Male , Mianserin/adverse effects , Mianserin/therapeutic use , Middle Aged , Mirtazapine , Paroxetine/adverse effects , Pilot Projects , Psychiatric Status Rating Scales , Remission Induction/methods , Treatment Outcome , Venlafaxine HydrochlorideABSTRACT
OBJECTIVE: To investigate the association between single nucleotide polymorphisms (SNPs) in cyclic adenosine monophosphate response element-binding protein(CREB1) gene and major depressive disorder (MDD). METHODS: We recruited 105 parent-offspring trios of Chinese descent, extracted whole blood genomic DNA, and genotyped the SNPs in rs10932201 and rs6740584 loci. Single-marker transmission disequilibrium test (TDT), pairwise SNP linkage disequilibrium(LD) and haplotype-based TDT were performed. RESULTS: No significant association with MDD was observed for SNPs rs10932201 and rs6740584 (P=0.1004 and P=0.4986). However, there was strong positive association between the rs10932201-rs6740584 haplotype and MDD (P=0.00003241), and both haplotypes of A-C and A-T were significantly associated with MDD (P=0.020 and P=0.00022). CONCLUSION: The rs10932201-rs6740584 haplotype of the CREB1 gene may play an important role in the pathogenesis of MDD.
Subject(s)
Cyclic AMP Response Element-Binding Protein/genetics , Depressive Disorder, Major/genetics , Polymorphism, Single Nucleotide/genetics , Female , Genetic Predisposition to Disease , Haplotypes , Humans , MaleABSTRACT
Genome-wide association studies (GWASs) have reported numerous associations between risk variants and major psychiatric disorders (MPDs) including schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD) and others. We reviewed all of the published GWASs, and extracted the genome-wide significant (p<10-6) and replicated associations between risk SNPs and MPDs. We found the associations of 6 variants located in 6 genes, including L type voltage-gated calcium channel (LTCCs) subunit alpha1 C gene (CACNA1C), that were genome-wide significant (2.0×10 -8 ≤p≤1.0×10 -6 ) and replicated at single-point level across at least two GWASs. Among them, the associations between MPDs and rs1006737 within CACNA1C are most robust. Thus, as a next step, the expression of the replicated risk genes in human hippocampus was analyzed. We found CACNA1C had significant mRNA expression in human hippocampus in two independent cohorts. Finally, we tried to elucidate the roles of venlafaxine and ω-3 PUFAs in the mRNA expression regulation of the replicated risk genes in hippocampus. We used cDNA chip-based microarray profiling to explore the transcriptome-wide mRNA expression regulation by ω-3 PUFAs (0.72/kg/d) and venlafaxine (0.25/kg/d) treatment in chronic mild stress (CMS) rats. ω-3 PUFAs and venlafaxine treatment elicited significant CACNA1C up-regulation. We concluded that CACNA1C might confer the genetic vulnerability to the shared depressive symptoms across MPDs and CACNA1C might be the therapeutic target for depressive endophenotype as well.
ABSTRACT
The genetic pathogenesis of major depressive disorder (MDD) has not been elucidated. It has been proposed that brain-derived neurotrophic factor (BDNF), as a member of the neurotrophin family, may be involved in the etiology and antidepressant response of MDD. The present study investigated the possible presence of an association between the BDNF gene and MDD. Single-marker transmission disequilibrium test (TDT), pairwise-SNP linkage disequilibrium (LD) and haplotype-based TDT analyses were performed on single nucleotide polymorphisms (SNPs) rs6265, rs10835210 and rs2030324 in 105 Chinese trios. No significant associations with MDD were demonstrated for three SNPs. Pairwise LD analysis revealed substantial LD among three SNPs. Multiple-marker TDT analysis indicated that there was no association between the haplotypes from rs6265-rs10835210-rs2030324 and MDD. The statistical power of the present study was calculated so we had an idea what kind of effects could be identified. We conclude that SNPs rs6265, rs10835210 and rs2030324 of the BDNF gene are unlikely to play a critical role in the pathogenesis of MDD.
Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Depressive Disorder, Major/genetics , Family Health , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide/genetics , Adult , Asian People/ethnology , Female , Gene Frequency , Genotype , Humans , Linkage Disequilibrium , Male , Middle Aged , Young AdultABSTRACT
OBJECTIVES: This study aimed to analyze (1) the cost-effectiveness of olanzapine orally disintegrating tablet (ODT) compared to olanzapine standard oral tablet (SOT) and (2) the cost-effectiveness of olanzapine-SOT compared to aripiprazole-SOT for patients with schizophrenia in China. METHODS: A microsimulation model was adapted from a healthcare payers' perspective. The model ran over a 1-year time horizon, using quarterly cycles. The costs of adverse events were acquired through a clinical expert panel. The average bidding prices in China of olanzapine-ODT, olanzapine-SOT, aripiprazole-SOT, and other switch alternatives were used. Inpatient and outpatient medical costs were sourced from the Urban Employee Basic Medical Insurance database in Tianjin. Additionally, adherence, efficacy, safety, and utility data were taken from the literature. Uncertainty of parameters were assessed through one-way and probabilistic sensitivity analyses. RESULTS: The total annual costs per patient in aripiprazole-SOT arm, olanzapine-SOT arm, and olanzapine-ODT arm are USD 2,296.05, USD 1,940.05, and USD 2,292.81, respectively. The average number of relapses per patient in 1 year in the aripiprazole-SOT arm, olanzapine-SOT arm, and olanzapine-ODT arm, are 0.734, 0.325, and 0.198, respectively. The quality-adjusted life years (QALYs) gained per patient in 1 year in the aripiprazole-SOT arm, olanzapine-SOT arm, and olanzapine-ODT arm are 0.714, 0.737, and 0.758, respectively. Consequently, (1) the incremental cost-effectiveness ratios (ICERs) of administrating olanzapine-ODT over olanzapine-SOT are USD 2,791.96 per relapse avoided and USD 16,798.39 per QALY gained; and (2) the ICERs of using olanzapine-SOT over aripiprazole-SOT are USD -870.39 per relapse avoided and USD -15,477.93 per QALY gained. All ICERs are under the willingness-to-pay threshold in China of USD 25,772.67. The sensitivity analyses confirmed the robustness of the results. CONCLUSION: As the first-line treatment for schizophrenia in China, olanzapine-ODT is cost-effective compared to olanzapine-SOT and olanzapine-SOT is cost-effective compared to aripiprazole-SOT.
Subject(s)
Antipsychotic Agents/economics , Antipsychotic Agents/therapeutic use , Aripiprazole/economics , Aripiprazole/therapeutic use , Schizophrenia/drug therapy , Antipsychotic Agents/administration & dosage , China , Cost-Benefit Analysis , Drug Compounding , Health Resources/economics , Health Resources/statistics & numerical data , Humans , Medication Adherence , Models, Econometric , Olanzapine , Quality-Adjusted Life Years , RecurrenceABSTRACT
Objectives: The nature of the diagnostic classification of mood disorder is a typical dichotomous data problem and the method of combining different dimensions of evidences to make judgments might be more statistically reliable. In this paper, we aimed to explore whether peripheral neurotrophic factors could be helpful for early detection of bipolar depression. Methods: A screening method combining peripheral biomarkers and clinical characteristics was applied in 30 patients with major depressive disorder (MDD) and 23 patients with depressive episode of bipolar disorder. By a model-based algorithm, some information was extracted from the dataset and used as a "model" to approach penalized regression model for stably differential diagnosis for bipolar depression. Results: A simple and efficient model of approaching the diagnosis of individuals with depressive symptoms was established with a fitting degree (90.58%) and an acceptable cross-validation error rate. Neurotrophic factors of our interest were successfully screened out from the feature selection and optimized model performance as reliable predictive variables. Conclusion: It seems to be feasible to combine different types of clinical characteristics with biomarkers in order to detect bipolarity of all depressive episodes. Neurotrophic factors of our interest presented its stable discriminant potentiality in unipolar and bipolar depression, deserving validation analysis in larger samples.